医療科学部

成瀬 寛之

ナルセ ヒロユキ  (naruse hiroyuki)

基本情報

所属
藤田医科大学 医療科学部 臨床病態解析学分野 教授
学位
博士(医学)

J-GLOBAL ID
200901082921426237
researchmap会員ID
5000025023

学歴

 1

論文

 130
  • Yuya Ishihara, Hiroyuki Naruse, Hidetsugu Fujigaki, Reiko Murakami, Tatsuya Ando, Kouhei Sakurai, Komei Uehara, Koki Shimomae, Eirin Sakaguchi, Hidekazu Hattori, Masayoshi Sarai, Junnichi Ishii, Ryosuke Fujii, Hiroyasu Ito, Kuniaki Saito, Hideo Izawa
    Vaccines 12(7) 786-786 2024年7月17日  
    Preexisting cardiovascular disease (CVD) is a pivotal risk factor for severe coronavirus disease 2019 (COVID-19). We investigated the longitudinal (over 1 year and 9 months) humoral and cellular responses to primary series and booster doses of mRNA COVID-19 vaccines in patients with CVD. Twenty-six patients with CVD who received monovalent mRNA COVID-19 vaccines were enrolled in this study. Peripheral blood samples were serially drawn nine times from each patient. IgG against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) was measured using an enzyme-linked immunosorbent assay. The numbers of interferon-γ-releasing cells in response to SARS-CoV-2 peptides were measured using an enzyme-linked immunospot assay. The RBD-IgG titers increased 2 weeks after the primary series and booster vaccination and waned 6 months after vaccination. The S1-specific T cell responses in patients aged < 75 years were favorable before and after booster doses; however, the Omicron BA.1-specific T cell responses were poor. These results suggest that regular vaccination is useful to maintain long-term antibody levels and has implications for booster dose strategies in patients with CVD. Additional booster doses, including Omicron variant-adapted mRNA vaccines, may be recommended for patients with CVD, regardless of age.
  • Eirin Sakaguchi, Hiroyuki Naruse, Yuya Ishihara, Hidekazu Hattori, Akira Yamada, Hideki Kawai, Takashi Muramatsu, Fumihiko Kitagawa, Hiroshi Takahashi, Junnichi Ishii, Masayoshi Sarai, Masanobu Yanase, Yukio Ozaki, Kuniaki Saito, Hideo Izawa
    Heliyon 10(13) e32452 2024年7月15日  
    The CHA2DS2 -VASc score is a vital clinical tool for evaluating thromboembolic risk in patients with atrial fibrillation (AF). This study investigated the efficacy of the CHA2DS2 -VASc score in a cohort of 737 heterogeneous patients (mean age: 63 years) receiving care in cardiac intensive care units (CICUs), with a creatinine-based estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m2 upon admission and discharge. Incident chronic kidney disease (CKD) was defined as the emergence of a new-onset eGFR<60 mL/min/1.73 m2, accompanied by a decline of >5 mL/min/1.73 m2 compared to that at discharge. The primary endpoint was the incidence of CKD, and the secondary endpoints included all-cause mortality, cardiovascular events, and progression to end-stage kidney disease. In this cohort, 210 (28 %) patients developed CKD. Multivariate analyses revealed that CHA2DS2 -VASc score was a significant independent predictor of incident CKD, regardless of the presence of AF. Integration of CHA2DS2 -VASc scores with eGFR enhanced the predictive accuracy of incident CKD, as evidenced by the improved C-index, net reclassification improvement, and integrated discrimination improvement values (all p < 0.05). Over the 12-month follow-up period, a composite endpoint was observed in 61 patients (8.3 %), with elevated CHA2DS2 -VASc scores being independently associated with this endpoint. In conclusion, CHA2DS2-VASc scores have emerged as robust predictors of both CKD incidence and adverse outcomes. Their inclusion substantially refined the 12-month risk stratification of patients with preserved renal function hospitalized in the CICUs.
  • 石原 裕也, 北川 文彦, 中村 和広, 久野 貴弘, 坂口 英林, 成瀬 寛之, 伊藤 弘康, 石井 潤一
    臨床化学 53(Suppl.1) 137-137 2024年7月  
  • Katsumi Iizuka, Kanako Deguchi, Chihiro Ushiroda, Kotone Yanagi, Yusuke Seino, Atsushi Suzuki, Daisuke Yabe, Hitomi Sasaki, Satoshi Sasaki, Eiichi Saitoh, Hiroyuki Naruse
    Nutrients 16(11) 1742-1742 2024年6月2日  査読有り
    In Japan, nutritional guidance based on food-recording apps and food frequency questionnaires (FFQs) is becoming popular. However, it is not always recognized that different dietary assessment methods have different nutritional values. Here, we compared the compatibility of dietary intake data obtained from an app with those obtained from FFQs in 59 healthy individuals who recorded information regarding their diet for at least 7 days per month using an app developed by Asken (Tokyo, Japan). The diurnal coefficient of variation in total energy and protein intake was 20%, but those for vitamins B12 and D were &gt;80%, reflecting the importance of 7 days of recording rather than a single day of recording for dietary intake analyses. Then, we compared the results of two FFQs—one based on food groups and one based on a brief self-administered diet history questionnaire—for 7 days, as recorded by the app. There was a correlation coefficient of &gt;0.4 for all the items except salt. Regarding the compatibility between the app and FFQs, the percentage errors for total energy and nutrients were &gt;40–50%, suggesting no agreement between the app and the two FFQs. In conclusion, careful attention should be paid to the impact of different dietary assessment methods on nutrient assessment.
  • 坂口 英林, 成瀬 寛之, 石井 潤一, 山田 晶, 河合 秀樹, 村松 崇, 原田 将英, 西村 豪人, 皿井 正義, 簗瀬 正伸, 井澤 英夫
    日本循環器学会学術集会抄録集 88回 PJ043-1 2024年3月  

MISC

 199

書籍等出版物

 17

講演・口頭発表等

 286

共同研究・競争的資金等の研究課題

 7